Below The Knee | Market Signal

OPENING SHOT

The Enforcement Era Continues in Earnest — and It's Landing on Wound Care (again).

This was the week the DOJ turned the rhetoric into a reckoning. The 2026 National Health Care Fraud Takedown — announced June 23 — charged 455 defendants across 45 states and territories for schemes involving over $6.5 billion in false claims. Wound care and amniotic allografts were not a footnote. They were the center of gravity. Eleven defendants charged across six federal districts. One single nurse practitioner in Texas allegedly billing $906 million in medically unnecessary allografts. Another in Sarasota charged in a $118 million scheme, including NFL stadium luxury boxes and $400,000 in fine art. Twelve South Florida clinics had more than $27 million seized — alleged "bust outs" billing for services never rendered. CMS Administrator Dr. Oz, RFK Jr., Acting AG Todd Blanche, and FBI Director Kash Patel were all at the press conference. This is no longer a regulatory story. It's a criminal enforcement story, with wound care squarely in the crosshairs.

The same week, the New York Times published an investigation into the broader skin substitute Medicare fraud pattern, landing at exactly the moment federal prosecutors are making arrests. Legacy Medical Consultants — a Fort Worth company — is named as having collected at least $2.6 billion from Medicare. Its vice president of sales was arrested Monday. The NYT story will have reached audiences far beyond this sector.

Meanwhile, on the M&A side, the biggest wound care deal of the year dropped Thursday: H.B. Fuller (NYSE: FUL), the world's largest pure-play adhesives maker, announced a recommended cash offer to acquire Advanced Medical Solutions Group (AIM: AMS) for £2.85 per share — implying a total enterprise value of £715 million. A 35% premium to the pre-offer close. AMS's stock had been under sustained pressure; its Woundcare segment had posted an 11% revenue decline in the most recent interim period. H.B. Fuller's thesis is an addressable market expansion of $15 billion, to $95 billion total. This is a strategic bet on tissue bonding and surgical adhesives, not a wound dressing bet — but it's the largest wound care-adjacent acquisition so far in 2026.

On the FDA front, Kerecis and Coloplast's guidance cut (announced in April, underlying dynamics playing out now) provides the most current public evidence of exactly how hard the $127/cm² rate fix is hitting commercial-stage CAMPs companies. Louisiana Medicaid updated its skin substitute coverage policy this week — adding a formal state-level layer to what is already a federal reimbursement story. The regulatory environment is not stabilizing. It is tightening from every direction simultaneously.

Here's the week.

BTK Intelligence Dashboard

Daily news and alerts. Customized watchlists and notifications. Capital signals including M&A, Deal Ledger, Deal Pipeline. Reimbursement Risk Assessment. Policy Trackers. Natural langugage AI-powered search queries. And more.

This isn't a report you read once. It's a living platform built exclusively for wound care, limb salvage, vascular intervention, and foot & ankle.

WOUND CARE

M&A | H.B. Fuller Acquires Advanced Medical Solutions in £715M Deal

H.B. Fuller Company (NYSE: FUL) announced a recommended cash offer to acquire Advanced Medical Solutions Group plc (AIM: AMS) for £2.85 per share, implying a total enterprise value of approximately £715 million — a 34.8% premium to AMS's closing price on May 20, the last trading day before the offer period began. AMS is a Cheshire-based developer and manufacturer of tissue-healing technologies across two segments: Surgical (tissue adhesives, sutures, haemostats, internal sealants, laparoscopic fixation — sold under LiquiBand, RESORBA, LiquiBandFix8, and Seal-G) and Woundcare (silver alginates, foams, hydrogels, antimicrobial dressings — sold under ActivHeal and white label). For the year ended December 31, 2025, AMS reported group revenue of £228.9 million, up 29%, driven largely by the full-year impact of the 2024 Peters Surgical acquisition. Its Woundcare segment had posted an 11% revenue decline in the most recent interim period, with an operating margin of just 6%. H.B. Fuller, the world's largest pure-play adhesives manufacturer, describes the transaction as expanding its addressable market by $15 billion to a total of $95 billion, adding approximately $300 million in annual revenues, and accessing AMS's portfolio of tissue bonding adhesives, tapes and dressings, and formulated biosurgicals. The company projects approximately $55 million in combined run-rate revenue and cost synergies by 2031. The acquisition is subject to merger control and foreign investment approvals and is expected to close by end of 2026.

The BTK read: This is a strategic adhesives and surgical business acquisition with a wound dressing business attached — not a wound care conviction bet. H.B. Fuller's stated rationale is tissue bonding, surgical sealants, and laparoscopic fixation technologies, not the ActivHeal dressing portfolio, which has been structurally underperforming. The 34.8% premium reflects where AMS's stock had drifted, not a premium to intrinsic value — the stock had been under pressure partly from Woundcare weakness. What this transaction signals for the sector: surgical and wound closure technologies remain attractive M&A targets; wound dressing businesses trading at distressed operating margins are acquirable if the surgical platform justifies the deal. Watch for how H.B. Fuller addresses the Woundcare segment operationally post-close. This could be a portfolio rationalization candidate or a turnaround target.

Capital | Nanordica Medical Raises €1.6M for Antibiotic-Free Chronic Wound Dressing

Estonian medtech company Nanordica Medical closed a €1.6 million round led by 2C Ventures, with participation from Specialist VC, Superangel, Amalfi, the Health Founders syndicate, and the EstBAN syndicate. Nanordica's Premotiv technology is a nanotechnology-based wound dressing combining copper and silver nanoparticles at concentrations designed to eliminate bacterial infection without damaging healthy skin cells — directly addressing what the company calls the longstanding trade-off between antimicrobial activity and skin cell safety. In a published randomized controlled trial of 30 diabetic foot ulcer patients, the dressing achieved a 43% reduction in wound area after one week of treatment versus 13% for standard silver dressings. A larger multicentered, double-blind, randomized clinical trial in diabetic foot ulcer patients currently has more than 120 patients enrolled. Nanordica plans to use the funding to complete clinical trials, secure CE marking, and advance toward European commercial launch.

The BTK read: The antimicrobial resistance angle is real and increasingly regulatory. Most existing antibacterial dressings are excluded from wound care treatment guidelines because they lack clinical evidence and use concentrations that impair healing — Nanordica is specifically targeting that gap. The published DFU data in the Journal of Wound Care is a meaningful credentialing step. This is a European-stage company; US regulatory pathway and commercial timing are the unknowns for anyone watching it from a US market perspective. But the mechanism (nanoparticle synergy avoiding traditional antibiotics) and the evidence trajectory warrant tracking. The 120-patient ongoing trial is the next datapoint that matters.

REIMBURSEMENT & POLICY

Reimbursement | Louisiana Medicaid Updates Skin Substitute Coverage Policy

Louisiana Medicaid issued an updated coverage policy for skin substitutes effective June 22, 2026, specifically addressing cellular and tissue-based products for chronic wounds. The policy covers products from Organogenesis (Affinity), MiMedx, Coloplast/Kerecis, Integra, and other manufacturers, with product-specific coverage determinations based on available clinical evidence. The state policy applies product-level coverage criteria — not simply deferring to federal Medicare coverage — and reflects Louisiana Medicaid's independent assessment of the evidentiary basis for individual skin substitute products and wound indications.

The BTK read: State Medicaid policies are moving on skin substitutes independently of CMS's ongoing federal coverage review. Louisiana's updated policy is a signal that state programs are building their own product-level coverage frameworks in a reimbursement environment where federal guidance has been deliberately delayed (the LCD withdrawal in December 2025 left coverage rules in place while cutting payment rates). For manufacturers of CAMPs products, state Medicaid coverage policies are now a distinct commercial variable — not a derivative of Medicare coverage — that requires active monitoring and engagement. Organogenesis, MiMedx, Coloplast/Kerecis, and Integra are the directly named players in the Louisiana update.

Finance | Coloplast Takes DKK 3B Kerecis Impairment — and Cuts Full-Year Guidance

Coloplast (NASDAQ Copenhagen: COLO B) revised its FY 2025/26 financial guidance in April, recognizing a DKK 3.0 billion goodwill impairment on Kerecis and cutting group organic growth expectations from approximately 7% to 5-6%. The revision cited a slower-than-expected recovery in the US outpatient skin substitute market following CMS's January 1, 2026 implementation of a fixed payment rate of $127/cm² for skin substitutes. Coloplast's Wound & Tissue Repair segment posted -2% organic growth in Q2. Kerecis, acquired by Coloplast in 2022 for approximately $1.3 billion, had previously been projected at approximately 25% organic growth for FY 2025/26; that figure was revised to approximately 10% in Q1 and then again to near-zero EBIT margin in the April guidance update. Coloplast indicated it will phase out its Shield brand in the Medicare outpatient setting — where it priced above the $127/cm² rate — and shift to an updated MariGen range. Approximately 20% of Kerecis revenue came from Medicare outpatient care.

The BTK read: The DKK 3.0 billion impairment represents roughly one-third of the total Kerecis acquisition value being written down within four years of closing. This is the clearest single financial data point on the magnitude of CMS reimbursement impact on a premium CAMPs product. Coloplast had positioned Kerecis as a differentiated, evidence-backed product priced below the old ASP reimbursement ceiling — and still had to write down a third of the goodwill because the outpatient market disruption exceeded management's projections. The product portfolio pivot to MariGen (which had always been better aligned to the $127/cm² rate structure) is the right commercial adaptation. The broader read for the sector: even the best-positioned CAMPs players are absorbing significant commercial disruption. Companies without Coloplast's diversified business model are facing this headwind with no cushion.

Fraud & Enforcement | DOJ's 2026 National Health Care Fraud Takedown: Wound Care at the Center

The Department of Justice announced on June 23 the 2026 National Health Care Fraud Takedown — the largest coordinated healthcare fraud enforcement action in DOJ history — charging 455 defendants across 56 federal districts and 45 states and territories for schemes involving over $6.5 billion in false claims. Ninety defendants were licensed medical professionals. Wound care allografts were the single largest fraud category by dollar volume, with 11 defendants charged across six federal districts for schemes involving more than $4 billion in Medicare billings and over $2 billion in actual payments. Key cases: in the Southern District of Texas, a Las Vegas nurse practitioner was charged in a $906 million scheme, running mobile wound clinics in four states, targeting elderly and hospice patients, and billing Medicare more than $1 million per patient on average for medically unnecessary amniotic wound allografts. Prosecutors allege she falsified records, accepted illegal kickbacks, and had approximately $35.2 million in assets seized, including a $594,000 Ferrari GTS and an $865,000 Bulgari necklace. In the Middle District of Florida, Sarasota nurse practitioner Leigh Tesar was charged in a $118 million scheme, with two referring nurses charged alongside her for accepting kickbacks. In the District of Arizona, charges were filed against a wound care graft company executive — following 15.5- and 14-year sentences obtained last year against the company's founders — for paying illegal kickbacks, bribes, and rebates that the DOJ estimates generated $24 million in personal proceeds. DOJ also seized more than $27 million from 12 South Florida clinics alleged to be "bust outs" billing for services never provided. Total assets seized across the takedown: more than $182 million. CMS simultaneously revoked the billing privileges of 1,403 providers.

The BTK read: Read the DOJ press release directly if you haven't. The wound allograft cases are not outliers — they are the signature story of this enforcement action. The shift from "pay and chase" to data-analytics-driven pre-payment interception, combined with the CMS $127/cm² rate reform that took effect January 1, is the full policy picture: the payment incentive has been removed and enforcement is now catching the actors who were still operating under the old structure. What this means commercially: any company or provider with wound allograft exposure should treat the compliance and documentation risk as existential. The DOJ's Data Analytics Team is detecting billing spikes in real time. The "allograft economics" that drove the abuse — 2,000% markups, 40% kickback structures — are now well-documented in federal filings. This takedown is not the end of enforcement action in wound care. It is the beginning of a sustained era.

Fraud & Enforcement | NYT Investigation: Skin Substitute Medicare Fraud — The Arrests Are Arriving

The New York Times published an investigation this week into the skin substitute Medicare fraud story as enforcement actions announced Monday began. The investigation named Legacy Medical Consultants, a Fort Worth, Texas company that collected at least $2.6 billion from Medicare, as a central actor. The company's vice president of sales, Brian Rowan, was charged Monday with offering illegal kickbacks, bribes, and rebates to providers using Legacy Medical's skin substitutes. The DOJ estimates he personally earned $24 million from the scheme. A separate case involving a Las Vegas nurse practitioner alleged she ran a chain of wound care clinics, accepted kickbacks from skin substitute manufacturers, shared kickback proceeds with referring physicians, and submitted more than $297 million in false claims — billing in some cases for patients who were in hospice. The NYT's framing is the story behind the DOJ numbers: Medicare spending on skin substitutes grew from approximately $250 million in 2019 to more than $10 billion in 2024 before the CMS rate reform took effect.

The BTK read: The NYT story reaches an audience orders of magnitude larger than any sector publication. When general-interest national media publishes a definitive fraud investigation on skin substitutes, the resulting reputational and political environment for the entire category shifts. Congressional attention, CMS scrutiny, and prosecutorial prioritization all follow mainstream media coverage of this magnitude. For legitimate CAMPs companies with defensible clinical evidence and clean commercial practices — Organogenesis, MiMedx, Kerecis, Integra — the enforcement wave is a market-clearing event that ultimately benefits them if they survive the payment disruption. For companies that cannot demonstrate clinical necessity at the patient level, the risk is now acute.

VASCULAR & LIMB SALVAGE

Regulatory | GuideAI Health Receives FDA 510(k) Clearance for VascularAssist AI Occlusion Triage

GuideAI Health Corp. received FDA 510(k) clearance on June 22 for VascularAssist Occlusion Triage, an AI-based Software as a Medical Device (SaMD) classified as a Computer-Aided Triage and Notification device (CADt). VAOT analyzes routine CT scans to identify and flag suspected peripheral vascular disease (PVD) and vascular occlusion in the lower extremities, prioritizing cases for radiologist review within existing imaging workflows. The software targets a fundamental failure mode in vascular care: PVD is frequently missed or under-reported on CT studies performed for other indications. In clinical performance testing supporting the clearance, VAOT achieved 95% patient-level sensitivity in 2D CT analysis and 94% in 3D CT analysis for identifying PAD-positive patients at a threshold of at least one lesion with 50% or greater stenosis. The company was founded by radiologists.

The BTK read: The clinical case for this product is straightforward: peripheral artery disease causes limb loss, and it is routinely missed on CT scans performed for other indications because radiologists are not systematically looking for it or don't have time to flag incidental findings. A CADt tool that flags these cases for prioritized review addresses a real workflow gap. The 95% sensitivity figure in 2D analysis is meaningful for a triage tool — the clinical requirement is high sensitivity with acceptable specificity, not perfect specificity. The commercial challenge is reimbursement and workflow integration; the hospital-based radiology pathway is real but navigating GPO contracting, EMR integration, and radiologist adoption takes time and capital. Watch for commercial partnerships with major health systems or radiology groups as the indicator that commercialization is moving at pace.

Regulatory | PorTal Access Receives FDA 510(k) Clearance for FLEXI-PORT Vascular Access Ports

PorTal Access (Miami) received FDA 510(k) clearance for the FLEXI-PORT family of implantable vascular access ports, designed for long-term vascular access in adult and pediatric patients. The FLEXI-PORT system is the first flexible implantable port on the market, available in 5Fr and 6Fr configurations, implantable in either the chest or arm, and requiring a smaller incision than conventional rigid titanium or hard plastic-based ports. The company positions the device for oncology patients requiring long-term chemotherapy access, arguing that nearly half of cancer patients do not receive chemo-ports due to procedural delays and complexity — a gap the FLEXI-PORT's design and placement flexibility is intended to address. PorTal raised a $7 million Series A in 2025 to support the 510(k) submission.

The BTK read: Vascular access port design has not seen meaningful innovation in years. The case for a flexible port with a smaller incision is primarily patient comfort and access-site flexibility — both legitimate clinical differentiators in a market where the incumbent titanium port experience is not universally positive. The 5Fr/6Fr configurations and chest/arm implantation options give clinicians real flexibility across patient populations. The commercial question is hospital adoption: this is a procedure-based product where clinical adoption depends on interventional radiology and surgical buy-in, and GPO contracting is the distribution bottleneck. Market entry against entrenched Bard, Smiths, and AngioDynamics positions will require a focused, proceduralist-driven launch strategy.

REGULATORY

Regulatory | FDA Hiring 2,200 to Rebuild After DOGE Cuts

The FDA announced it is actively recruiting approximately 2,200 new employees to rebuild its workforce following the staffing reductions implemented under the DOGE initiative last year. The agency has secured approximately 600 new hires to date and is seeking an additional 1,600. Interim agency leadership has framed the hiring effort as necessary to restore both operational capacity and internal morale following what BioSpace characterized as "more than a year of intense attrition." The recruiting effort covers scientific reviewers, inspectors, and operational staff across CDER, CBER, and CDRH.

The BTK read: FDA review timelines for 510(k) submissions, Breakthrough Device requests, and pre-submission feedback cycles have been measurably affected by the staffing disruption of the past 18 months. A 2,200-person rebuild signals intent, but hiring cycles are slow and institutional knowledge takes years to replace. For companies in the BTK universe with active regulatory submissions — particularly those pursuing 510(k) clearance or de novo designation in wound care, vascular, or foot and ankle — plan for continued variability in review timelines through at least mid-2027. The GuideAI and PorTal clearances this week are positive signals that the FDA is still processing submissions, but the pipeline remains under capacity.

FINANCE | CAPITAL ACTIVITY

M&A

BTK Wound Care Fund™ — Now Live on the Dashboard

The BTK Wound Care Fund™ is a model-traded portfolio of 32 active holdings, tracking the companies that define this market. Real-time pricing. Performance against the S&P 500, Dow, and Nasdaq. Top 5 and Bottom 5 movers every week.

📅 UPCOMING EVENTS

June 25–28 | Anaheim, CA — The Western Foot & Ankle Conference 2026 — Disneyland Hotel & Convention Center

August 6–9 | Nashville, TN — APMA Annual Scientific Meeting (The National) — Gaylord Opryland

September 10–11 | New Orleans, LA — IPAWS & Tissue Repair Summit (Kernexus) — The Ritz-Carlton

September 14–16 | Louisville, KY — NAWCO HEAL Conference 2026

September 23–27 | Kuala Lumpur, Malaysia — WUWHS 2026

October 15–18 | Las Vegas, NV — SAWC Fall 2026 — Caesars Palace

October 22–24 | Anaheim, CA — DFCon 2026 — JW Marriott

November 6 | Virtual — WoundCon Fall 2026

December 9–12 | Phoenix, AZ — Desert Foot Multi-Disciplinary Limb Salvage & Wound Care Conference

Not subscribed? → newsletter.belowtheknee.co · Forward this to one person in your network who works in this space.

See you next week - Scott